



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Revised Scope and updated Toolkit

Clinical Data Publication (Policy 0070) – Step 2 – EMA webinar

Presented by Karen Quigley on 14 November 2024

Head of Clinical Data Publication, Transparency Department, Stakeholders and Communication Division



Current and proposed Scope

Current Step 1

New active substances and Covid transparency measures

Proposed Step 2

All new MAAs including negative opinions, withdrawn applications, line extensions and major clinical Type II variations (extension of indications) from Q2 2025


Exclude all biosimilars, hybrids and generics

Continue Covid procedures and any new public health emergencies that may arise




CDP Data from 2020 to Oct 2024

Clinical Data Publications



Clinical Data Website Users





Updated Toolkit

- **External Guidance** - under review to publish early 2025
- Questions and answers (**Q&A**) document - published July 2023 – update in 2025
- EMA internal new **tracking tool** to manage applications
- **Document identification system** developed in house - prepare list of documents in scope and provide with invitation letter
- **Invitation letter** – detailed procedural guidance – anonymisation template
- **Meetings** to assist preparation of packages – CCI – anonymisation strategy
- Collaboration with **Health Canada** align processes – workshare



Any questions?

Join at
slido.com
#2883 085

 Passcode: **zjc1xf**



<https://app.sli.do/event/eQXpoY4Tkyb5mVkMMDnuK1>